Polynovo Limited · ASX:PNV
Polynovo — FY2024 Earnings Presentation
13 slides from Polynovo's earnings presentation, Aug 23, 2024
Slide 1: FY24 Results: Accelerating Global Impact
For personal use only FY24 Results (in conjunction with Appendix 4E) Accelerating Global Impact 23 August 2024
Slide 2: Disclaimer
Disclaimer For personal use only This presentation has been prepared by PolyNovo Limited and is provided for general information purposes only. No party other than PolyNovo has authorised or caused the issue of this document, or takes responsibility for, or makes any statements, representations or u
Slide 3: Extending the Depth and Breadth of Global Footprint
Extending the Depth and Breadth of Global Footprint For personal use only CY25: Japan market entry 41 Countries U.K. Germany 50,000+ Patients U.S. 280+ Independent Articles and Abstracts Australia New Zealand FY25: India 120 Patients Enrolled in tenders/reimbursement BARDA Trial Meaningfully Differe
Slide 4: FY24 Financial Results
For personal use only FY24 Financial Results 4
Slide 5: Total Revenue Growth
Total Revenue Growth For personal use only Total revenue growth 400 Highlights: 284 300 • Total revenue including BARDA of A$104.8m 215 57.5% 149 200 • Up 57.5% on STLY of A$66.5m 91 60 58.8% $104.8 100 • NovoSorb product sales of A$92.0m 42.8% 0 • Up 54.5% on STLY of A$59.6m 32.0% $66.5 $41.9 -100
Slide 6: Product Sales by Region
Product Sales by Region For personal use only Product sales by region Highlights: 54.5% • Record FY24 sales A$92.0m up 54.5% on STLY of 70.0% A$59.6m. $92.0 60.0% 58.3% • Strong momentum with record monthly sales in April 50.0% of A$9.2m and A$9.8m in May 2024 47.6% $59.6 40.0% • Strong growth in U.
Slide 7: Road to Profitability
Road to Profitability For personal use only Revenue, opex, NPAT Highlights: Revenue (m) • NPAT A$5.3m vs. STLY loss (A$4.9m) Opex - R&D (m) 57.5% • Revenue growth 57.5% vs. Opex up 45.7% Opex - other (m) • Positive cash flow from operations A$3.7m vs. NLAT/NPAT (m) $104.8 STLY (A$6.6m) $97.6 58.8% $
Slide 8: NovoSorb: From Platform Technology to Products
NovoSorb: From Platform Technology to Products For personal use only Burn Surgeons • 1mm, 4mm, 6mm • Immediate STSG Complex • Particulate (contouring, • Antimicrobial Plastic and Reconstruction, Graftable wounds tunnelling) Trauma Surgeons Implantable Surgical • Simple Hernia (mesh • Complex hernia
Slide 9: Next Generation New Standard of Care
For personal use only Next Generation New Standard of Care Platform technology: Graftable & Implantable Capital efficient Growth and Scaling 9
Slide 10: For personal use only
For personal use only
Slide 11: Capital Efficient Growth
Capital Efficient Growth For personal use only Cash flow breakdown Highlights: • A$45.9m cash on hand and cash equivalents • Cashflow from operations A$3.7m vs. STLY (A$6.6m) • Capex to increase in FY25 and FY26 for construction of new manufacturing facility in Port Melbourne • Continue to invest in
Slide 12: FY24 Financial Results
FY24 Financial Results For personal use only Highlights: • Revenue up 57.5% • Product sales up 54.5% • EBITDA A$3.6m (FY23: A$2.8m loss) • Net profit after tax A$5.3m (FY23: A$4.9m loss) 12
Slide 13: Appendix
For personal use only Appendix 13